1: Yamagata Y, Aikou S, Fukushima T, Kataoka H, Seto Y, Esumi H, Kaminishi M, Goldenring JR, Nomura S. Loss of HGF activator inhibits foveolar hyperplasia induced by oxyntic atrophy without altering gastrin levels. Am J Physiol Gastrointest Liver Physiol. 2012 Dec 1;303(11):G1254-61. doi: 10.1152/ajpgi.00107.2012. Epub 2012 Oct 11. PubMed PMID: 23064758; PubMed Central PMCID: PMC4888532.
2: Fernandes RA, Nallasivam JL. Enantioselective allylation of imines catalyzed by newly developed (-)-β-pinene-based π-allylpalladium catalyst: an efficient synthesis of (R)-α-propylpiperonylamine and (R)-pipecolic acid. Org Biomol Chem. 2012 Oct 14;10(38):7789-800. doi: 10.1039/c2ob26188j. PubMed PMID: 22910971.
3: Weis VG, Sousa JF, LaFleur BJ, Nam KT, Weis JA, Finke PE, Ameen NA, Fox JG, Goldenring JR. Heterogeneity in mouse spasmolytic polypeptide-expressing metaplasia lineages identifies markers of metaplastic progression. Gut. 2013 Sep;62(9):1270-9. doi: 10.1136/gutjnl-2012-302401. Epub 2012 Jul 7. PubMed PMID: 22773549; PubMed Central PMCID: PMC3762676.
4: Nam KT, O'Neal RL, Coffey RJ, Finke PE, Barker N, Goldenring JR. Spasmolytic polypeptide-expressing metaplasia (SPEM) in the gastric oxyntic mucosa does not arise from Lgr5-expressing cells. Gut. 2012 Dec;61(12):1678-85. doi: 10.1136/gutjnl-2011-301193. Epub 2011 Dec 23. PubMed PMID: 22198711; PubMed Central PMCID: PMC3767919.
5: Nam KT, Lee HJ, Sousa JF, Weis VG, O'Neal RL, Finke PE, Romero-Gallo J, Shi G, Mills JC, Peek RM Jr, Konieczny SF, Goldenring JR. Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology. 2010 Dec;139(6):2028-2037.e9. doi: 10.1053/j.gastro.2010.09.005. Epub 2010 Sep 18. PubMed PMID: 20854822; PubMed Central PMCID: PMC2997152.
6: Quante M, Marrache F, Goldenring JR, Wang TC. TFF2 mRNA transcript expression marks a gland progenitor cell of the gastric oxyntic mucosa. Gastroenterology. 2010 Dec;139(6):2018-2027.e2. doi: 10.1053/j.gastro.2010.08.003. Epub 2010 Aug 12. PubMed PMID: 20708616; PubMed Central PMCID: PMC2997174.
7: Aikou S, Fukushima Y, Ogawa M, Nozaki K, Saito T, Matsui T, Goldenring JR, Kaminishi M, Nomura S. Alterations in gastric mucosal lineages before or after acute oxyntic atrophy in gastrin receptor and H2 histamine receptor-deficient mice. Dig Dis Sci. 2009 Aug;54(8):1625-35. doi: 10.1007/s10620-009-0832-2. Epub 2009 Jun 9. PubMed PMID: 19507031.
8: Nozaki K, Weis V, Wang TC, Falus A, Goldenring JR. Altered gastric chief cell lineage differentiation in histamine-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1211-20. doi: 10.1152/ajpgi.90643.2008. Epub 2009 Apr 9. PubMed PMID: 19359424; PubMed Central PMCID: PMC2697940.
9: Nozaki K, Ogawa M, Williams JA, Lafleur BJ, Ng V, Drapkin RI, Mills JC, Konieczny SF, Nomura S, Goldenring JR. A molecular signature of gastric metaplasia arising in response to acute parietal cell loss. Gastroenterology. 2008 Feb;134(2):511-22. doi: 10.1053/j.gastro.2007.11.058. Epub 2007 Dec 4. PubMed PMID: 18242217; PubMed Central PMCID: PMC2857727.
10: Nam KT, Varro A, Coffey RJ, Goldenring JR. Potentiation of oxyntic atrophy-induced gastric metaplasia in amphiregulin-deficient mice. Gastroenterology. 2007 May;132(5):1804-19. Epub 2007 Mar 24. PubMed PMID: 17484876.
11: Goldenring JR, Nomura S. Differentiation of the gastric mucosa III. Animal models of oxyntic atrophy and metaplasia. Am J Physiol Gastrointest Liver Physiol. 2006 Dec;291(6):G999-1004. Review. PubMed PMID: 17090722.
12: Ogawa M, Nomura S, Car BD, Goldenring JR. Omeprazole treatment ameliorates oxyntic atrophy induced by DMP-777. Dig Dis Sci. 2006 Mar;51(3):431-9. PubMed PMID: 16614949.
13: Ogawa M, Nomura S, Varro A, Wang TC, Goldenring JR. Altered metaplastic response of waved-2 EGF receptor mutant mice to acute oxyntic atrophy. Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G793-804. Epub 2005 Nov 23. PubMed PMID: 16306133.
14: Nomura S, Yamaguchi H, Ogawa M, Wang TC, Lee JR, Goldenring JR. Alterations in gastric mucosal lineages induced by acute oxyntic atrophy in wild-type and gastrin-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2005 Feb;288(2):G362-75. PubMed PMID: 15647607.
15: Buckley D, Haas MJ, Scholz TH, Sigvardson KW. Isolation and identification of a degradation product in a capsule formulation containing the elastase inhibitor, DMP 777. J Pharm Biomed Anal. 2001 Feb;24(4):651-7. PubMed PMID: 11272322.
16: Goldenring JR, Ray GS, Coffey RJ, Meunier PC, Haley PJ, Barnes TB, Car BD. Reversible drug-induced oxyntic atrophy in rats. Gastroenterology. 2000 Jun;118(6):1080-93. PubMed PMID: 10833483.
17: Dwyer TM, Farley JM. Human neutrophil elastase releases two pools of mucinlike glycoconjugate from tracheal submucosal gland cells. Am J Physiol Lung Cell Mol Physiol. 2000 Apr;278(4):L675-82. PubMed PMID: 10749744.
18: Zagrobelny J, Matuszewski BK, Kline WF, Vincent SH. Separation of the four stereoisomers of a potent inhibitor (L-694,458) of human leukocyte elastase and its determination in human plasma using achiral/chiral chromatography with column switching. J Pharm Biomed Anal. 1998 Sep 1;17(6-7):1057-64. PubMed PMID: 9884195.
19: Macdonald SJ, Belton DJ, Buckley DM, Spooner JE, Anson MS, Harrison LA, Mills K, Upton RJ, Dowle MD, Smith RA, Molloy CR, Risley C. Syntheses of trans-5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles and trans-5-oxo-hexahydro-furo[3,2-b]pyrroles (pyrrolidine trans-lactams and trans-lactones): new pharmacophores for elastase inhibition. J Med Chem. 1998 Oct 8;41(21):3919-22. PubMed PMID: 9767628.
20: Luffer-Atlas D, Vincent SH, Painter SK, Arison BH, Stearns RA, Chiu SH. Orally active inhibitors of human leukocyte elastase. III. Identification and characterization of metabolites of L-694,458 by liquid chromatography-tandem mass spectrometry. Drug Metab Dispos. 1997 Aug;25(8):940-52. PubMed PMID: 9280402.